Insider Selling: Icon (NASDAQ:ICLR) CEO Sells $62,674.74 in Stock

Icon Plc (NASDAQ:ICLR) CEO Barry Edward Balfe sold 382 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $164.07, for a total value of $62,674.74. Following the completion of the transaction, the chief executive officer owned 4,804 shares of the company’s stock, valued at approximately $788,192.28. This represents a 7.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Up 0.2%

Shares of NASDAQ:ICLR opened at $167.48 on Friday. The company has a market capitalization of $12.82 billion, a price-to-earnings ratio of 39.31, a price-to-earnings-growth ratio of 6.93 and a beta of 1.21. The company has a 50 day moving average of $162.22 and a two-hundred day moving average of $134.04. Icon Plc has a 52-week low of $66.57 and a 52-week high of $203.91. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23.

Icon (NASDAQ:ICLR) last posted its earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The business had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2 billion. During the same period in the previous year, the company posted $3.26 earnings per share. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, analysts forecast that Icon Plc will post 9.57 earnings per share for the current fiscal year.

Key Headlines Impacting Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue of $2.06 billion topped estimates of $2.00 billion. Revenue also rose 2.3% year over year, indicating continued demand for its outsourced clinical-research services.
• Positive Sentiment: Analyst support remains a potential catalyst. BMO Capital Markets raised its price target to $187, Mizuho lifted its target to $190, and William Blair upgraded the stock to “strong buy.” The broader analyst consensus is “Hold,” with an average target of $170.40. Analyst coverage article
• Positive Sentiment: Institutional ownership is high at 95.61%, and several investment firms recently initiated or increased positions in ICLR. The stock is also trading above its 50-day and 200-day moving averages, reflecting favorable recent momentum.
• Neutral Sentiment: CEO Barry Balfe, CFO Nigel Clerkin and several directors sold shares totaling roughly $1.6 million at prices near $164.07–$164.29. The filings state that the sales were made to cover tax-withholding obligations connected with vested equity awards, and the insiders retained shares afterward, reducing the negative signal. Icon insider sales article
• Negative Sentiment: Although revenue beat estimates, quarterly EPS fell from $3.26 in the prior-year period, highlighting earnings pressure. ICLR also trades at a relatively demanding valuation, with a price-to-earnings ratio near 39 and a PEG ratio above 6, leaving the stock vulnerable if growth or guidance weakens.

Hedge Funds Weigh In On Icon

A number of hedge funds have recently added to or reduced their stakes in ICLR. EFG International AG bought a new position in shares of Icon in the 4th quarter worth about $27,000. Abound Financial LLC acquired a new stake in Icon during the fourth quarter worth about $54,000. GAMMA Investing LLC raised its stake in Icon by 21.4% during the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after acquiring an additional 69 shares during the period. Johnson Financial Group Inc. bought a new position in Icon in the third quarter worth about $71,000. Finally, Quadrant Capital Group LLC acquired a new position in Icon in the third quarter valued at approximately $78,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Royal Bank Of Canada raised Icon from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $126.00 to $185.00 in a report on Thursday, June 25th. William Blair raised shares of Icon to a “strong-buy” rating in a research report on Thursday, July 30th. Mizuho lifted their price target on shares of Icon from $180.00 to $190.00 and gave the stock an “outperform” rating in a research note on Friday, June 26th. Piper Sandler downgraded shares of Icon to a “neutral” rating in a research note on Thursday, May 28th. Finally, Citigroup raised their price objective on shares of Icon from $165.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Icon currently has a consensus rating of “Hold” and a consensus price target of $170.40.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.